Opthea Limited (OPT)

Overview

Opthea Limited is a clinical stage biopharmaceutical company based in South Yarra, Australia, specializing in the development and commercialization of novel therapeutic solutions for eye diseases. Initially founded in 1984 as Circadian Technologies Limited, the company underwent a name change to Opthea Limited in December 2015. Focused on leveraging its extensive intellectual property portfolio, which includes Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3, Opthea is at the forefront of addressing diseases associated with abnormal blood and lymphatic vessel growth, as well as vascular leakage.

Products and Services

• Sozinibercept (OPT 302)

A leading product candidate from Opthea, Sozinibercept (OPT 302), embodies a novel approach to treating eye diseases by acting as a soluble form of the vascular endothelial growth factor receptor-3 (VEGFR-3). The drug is presently in Phase 3 clinical development, targeting major eye conditions such as wet age-related macular degeneration and diabetic macular edema. These diseases are characterized by the abnormal growth of blood vessels in the eye, leading to vision loss. By inhibiting VEGFR-3, Sozinibercept aims to control vessel proliferation and leakage, addressing the underlying cause of these conditions.